ICON Public (ICLR) Set to Announce Earnings on Wednesday

ICON Public (NASDAQ:ICLR - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, October 23rd. Analysts expect the company to announce earnings of $3.72 per share for the quarter. ICON Public has set its FY24 guidance at $15.00-$15.20 EPS.Parties that wish to register for the company's conference call can do so using this link.

ICON Public (NASDAQ:ICLR - Get Free Report) last announced its earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.68 by $0.07. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same quarter in the previous year, the firm posted $2.96 earnings per share. ICON Public's revenue was up 4.1% compared to the same quarter last year. On average, analysts expect ICON Public to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

ICON Public Stock Performance

ICLR stock traded down $1.27 on Wednesday, reaching $293.60. 437,186 shares of the company were exchanged, compared to its average volume of 571,195. The firm has a market capitalization of $24.22 billion, a PE ratio of 35.72, a PEG ratio of 1.35 and a beta of 1.22. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.31 and a quick ratio of 1.31. The stock's fifty day moving average price is $304.38 and its 200 day moving average price is $312.72. ICON Public has a 12 month low of $221.20 and a 12 month high of $347.72.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ICLR. Barclays lowered their price target on shares of ICON Public from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday. Truist Financial lowered their price target on shares of ICON Public from $383.00 to $363.00 and set a "buy" rating on the stock in a report on Monday. Redburn Atlantic began coverage on shares of ICON Public in a report on Monday. They issued a "neutral" rating and a $311.00 price target on the stock. StockNews.com lowered shares of ICON Public from a "buy" rating to a "hold" rating in a report on Thursday, September 19th. Finally, Leerink Partners started coverage on shares of ICON Public in a report on Wednesday, September 18th. They issued an "outperform" rating and a $379.00 price target on the stock. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $346.09.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.